Eupraxia Pharmaceuticals Secures $63.2M in New Offering, Extends Cash Runway to H2 2028 Amidst Positive Clinical Progress

summarizeSummary

Eupraxia Pharmaceuticals reported increased net losses for 2025 but significantly extended its cash runway into H2 2028 through two substantial public offerings totaling over $140 million. The company also announced positive clinical data for its lead EoE candidate, EP-104GI, and a strategic shift to prioritize its development.

check_boxKey Events

• Successful 2026 Public Offering

  The company closed a public offering on February 20, 2026, raising approximately $63.2 million in gross proceeds from the issuance of common shares and pre-funded warrants. This follows a $80.5 million offering in September 2025.

• Extended Cash Runway

  With the proceeds from recent offerings, the company anticipates its cash resources will be sufficient to fund planned operations into the second half of 2028, significantly de-risking near-term liquidity concerns.

• Positive EP-104GI Clinical Data & Phase 3 Plans

  Eupraxia announced positive tissue health data from its RESOLVE trial for EP-104GI in EoE, demonstrating near-complete improvement on biopsy in the highest dosed group. The company plans to initiate a Phase 3 program for EP-104GI.

• Strategic Shift for EP-104IAR Program

  The company is evaluating funding alternatives for the continued development of EP-104IAR (Osteoarthritis) and intends to use capital previously identified for this program to advance EP-104GI, indicating a strategic prioritization.

auto_awesomeAnalysis

Eupraxia Pharmaceuticals filed its annual report for the fiscal year ended December 31, 2025, revealing a net loss of $38.6 million for the year, an increase from $25.5 million in 2024, driven by higher research and development and general and administrative expenses. Despite the increased losses, the company significantly bolstered its financial position through two major capital raises. A public offering in September 2025 generated approximately $80.5 million, and a subsequent offering that closed on February 20, 2026, raised approximately $63.2 million in gross proceeds. These financings, combined with existing cash, are projected to fund operations into the second half of 2028, providing crucial runway for a clinical-stage biotechnology company. The company also reported positive tissue health data from its ongoing RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) and plans to advance this program to Phase 3. Concurrently, Eupraxia is evaluating funding alternatives for EP-104IAR (Osteoarthritis) and intends to reallocate capital previously earmarked for it to EP-104GI, signaling a strategic prioritization of its EoE program.